Natural Alternatives International, Inc. (NAII) AI Stock Analysis

Established in 1980 and based in Carlsbad, California, Natural Alternatives International, Inc. formulates, manufactures, and distributes nutritional supplements globally across regions including the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates through two main segments: Private-Label Contract Manufacturing and Patent and Trademark Licensing. It provides customized product formulation, clinical study design, regulatory compliance, packaging solutions, and testing for vitamins, minerals, and herbal supplements in forms like capsules, tablets, wafers, and powders. It also markets beta-alanine ingredients under the CarnoSyn and SR CarnoSyn brands to support athletic performance and muscle function.

Annual revenue dropped from $171.0M in FY2022 to $113.8M in FY2024 before rebounding to $129.9M in FY2025 and $141.4M in FY2026, marking an 8.9% annual gain. Over the 5-year period from FY2021 to FY2026, revenue recorded a CAGR of -4.6%. Profitability weakened over this period, with gross margin contracting from 17.8% in FY2022 to 5.5% in FY2026. Operating margin fell from 8.0% in FY2022 to -6.4% in FY2026, and net income declined from $10.7M to -$20.7M, resulting in an EPS of -$1.71. For the latest quarter ended June 30, 2026, quarterly revenue grew 1.9% year-over-year, while quarterly earnings grew 74.1%.

As of June 30, 2026, the company held $7.4M in cash and short-term investments against total debt of $50.0M, resulting in net debt of $42.6M and a debt-to-equity ratio of 1.00. Total assets stood at $126.4M, with shareholders' equity at $50.0M and a current ratio of 1.73. During FY2026, operating cash flow was -$8.9M, which contributed to free cash flow of -$12.6M after capital expenditures of $3.7M. The company also allocated $89,000 to share buybacks, with its share count decreasing 3.0% over five years.

At a last close of $1.15 on October 16, 2026, Natural Alternatives International holds a market capitalization of $7.2M and an enterprise value of $67.6M. The stock trades at a price-to-sales multiple of 0.1x and a forward P/E of 13.6x, compared to 0.7x and 14.3x for the median of its US-listed Consumer Defensive peers. Its EV-to-EBITDA stands at 75.0x, above the peer median of 11.7x. Over the past year, the shares fell 57.2%, trailing the S&P 500 return of 16.8%, and lag the broader market over five years with a -91.5% return versus 83.0% for the index.

Natural Alternatives International is scheduled to report its next earnings on November 11, 2026. The stock trades at a forward P/E of 13.6x and a PEG ratio of 5.41, based on forward projections. In the latest quarter ended June 30, 2026, the company posted quarterly earnings growth of 74.1% year-over-year alongside quarterly revenue growth of 1.9%. Specific Wall Street analyst consensus rating counts and price targets are currently unavailable for the company, while its last closing price was $1.15 on October 16, 2026.

This page is an AI-written research summary of Natural Alternatives International, Inc. (NAII). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NAII income statement, NAII balance sheet, NAII key metrics, NAII chart. See the NAII stock overview for the latest quote and news.